(AOF) – OSE Immunotherapeutics has announced the departure of Alexis Peyroles as CEO of the company. Dominique Costantini, currently Chair of the OSE Immunotherapeutics Board of Directors and Chief Executive Officer from 2012 to 2018, has been appointed Interim Chief Executive Officer, effective immediately. The search for a new CEO has begun with the help of a leading international recruitment firm.
Alexis Peyroles resigned for health reasons, he will remain involved in the advances of OSE Immunotherapeutics. He will continue to support the company for the next few months through a consulting assignment to ensure a smooth handover.
During this transition period, Dominique Costantini will rely on the reinforced management team of OSE Immunotherapeutics, in particular Laurence de Schoulepnikoff, today “chief business officer”, appointed director of operations, positions she previously held at AMAL Therapeutics.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.